| # | Drug | Count |
|---|---|---|
| 0 | TACROLIMUS | 29 |
| 1 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 29 |
| 2 | TACROLIMUS OINTMENT 0.1% | 29 |
| 3 | ADALIMUMAB | 23 |
| 4 | MYCOPHENOLATE MOFETIL | 19 |
| 5 | RITONAVIR | 19 |
| 6 | DARUNAVIR | 13 |
| 7 | PREDNISONE | 13 |
| 8 | METHOTREXATE SODIUM | 10 |
| 9 | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | 9 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NELFINAVIR MESYLATE | 4 | 0.0019 |
| 1 | ETRAVIRINE | 7 | 0.0016 |
| 2 | RALTEGRAVIR | 8 | 0.0015 |
| 3 | PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE | 1 | 0.0015 |
| 4 | MARAVIROC | 3 | 0.0013 |
| 5 | TESTOSTERONE ENANTHATE | 2 | 0.0012 |
| 6 | DARUNAVIR | 13 | 0.0009 |
| 7 | PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION | 1 | 0.0008 |
| 8 | ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE | 3 | 0.0005 |
| 9 | IMIQUIMOD | 1 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CCR5 Co-receptor Antagonist [EPC] | 3 | 0.0013 |
| 1 | Protease Inhibitor [EPC] | 20 | 0.0004 |
| 2 | Cytochrome P450 3A Inhibitor [EPC] | 21 | 0.0003 |
| 3 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 8 | 0.0003 |
| 4 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 13 | 0.0003 |
| 5 | Cannabinoid [EPC] | 2 | 0.0002 |
| 6 | Antihypoglycemic Agent [EPC] | 1 | 0.0002 |
| 7 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 25 | 0.0002 |
| 8 | Osmotic Diuretic [EPC] | 1 | 0.0002 |
| 9 | Sulfone [EPC] | 2 | 0.0002 |